PMID- 31872548
OWN - NLM
STAT- MEDLINE
DCOM- 20200626
LR  - 20200626
IS  - 1545-5017 (Electronic)
IS  - 1545-5009 (Linking)
VI  - 67
IP  - 4
DP  - 2020 Apr
TI  - Causes of early death and treatment-related death in newly diagnosed pediatric 
      acute myeloid leukemia: Recent experiences of the Dutch Childhood Oncology Group.
PG  - e28099
LID - 10.1002/pbc.28099 [doi]
AB  - BACKGROUND: With the current more effective treatment regimens for pediatric 
      acute myeloid leukemia (AML), research on early death (ED), treatment-related 
      mortality (TRM), and toxicity becomes increasingly important. The aim of this 
      study was to give an overview of the frequency, clinical features, and risk 
      factors associated with ED and TRM in first complete remission (CR1) during the 
      last three consecutive treatment protocols of the Dutch Childhood Oncology Group 
      (DCOG) between 1998 and 2014. METHODS: Incidence and risk factors associated with 
      ED and TRM in CR1 were retrospectively studied in 245 patients treated according 
      to the Dutch ANLL-97/AML-12 (n = 118), AML-15 (n = 60), or DB AML-01 (n = 67) 
      protocols. RESULTS: The incidence of ED was, respectively, 5.1%, 6.7%, and 3.0% 
      excluding deaths before treatment (P = NS), and 7.4%, 11.1%, and 4.4% including 
      deaths before the onset of treatment. Severe underweight at initial diagnosis was 
      significantly associated with more frequent ED. When relapse was included as a 
      competing risk, cumulative incidence of death in CR1 were 5.9%, 5.0%, and 4.6% 
      for ANLL97, AML15, and DB01, respectively (P = NS). The most important cause of 
      TRM included infectious and SCT-related complications. CONCLUSION: We report 
      relatively stable rates of ED and TRM in CR1 in the latest completed DCOG 
      protocols for newly diagnosed AML patients. The most important causes of TRM were 
      SCT- or infection-related, warranting further evaluation and awareness.
CI  - (c) 2019 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals, Inc.
FAU - Klein, Kim
AU  - Klein K
AUID- ORCID: 0000-0002-9794-1071
AD  - Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Pediatric 
      Oncology, Cancer Center Amsterdam, Amsterdam, The Netherlands.
AD  - University Medical Center Utrecht/Wilhelmina Children's Hospital, Utrecht, The 
      Netherlands.
AD  - Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
FAU - van Litsenburg, Raphaele R L
AU  - van Litsenburg RRL
AUID- ORCID: 0000-0003-1779-6159
AD  - Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Pediatric 
      Oncology, Cancer Center Amsterdam, Amsterdam, The Netherlands.
AD  - Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
FAU - de Haas, Valerie
AU  - de Haas V
AD  - Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
AD  - Dutch Childhood Oncology Group, The Hague, The Netherlands.
FAU - Dors, Natasja
AU  - Dors N
AD  - Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
AD  - Radboud University Medical Center, Nijmegen, The Netherlands.
FAU - van den Heuvel-Eibrink, Marry M
AU  - van den Heuvel-Eibrink MM
AD  - Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
FAU - Knops, Rutger R G
AU  - Knops RRG
AD  - Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Pediatric 
      Oncology, Cancer Center Amsterdam, Amsterdam, The Netherlands.
AD  - Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
FAU - Tissing, Wim J E
AU  - Tissing WJE
AD  - Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
AD  - Beatrix Children's Hospital, University of Groningen, University Medical Center 
      Groningen, Groningen, The Netherlands.
FAU - Versluys, Birgitta A
AU  - Versluys BA
AD  - University Medical Center Utrecht/Wilhelmina Children's Hospital, Utrecht, The 
      Netherlands.
AD  - Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
FAU - Zwaan, C Michel
AU  - Zwaan CM
AD  - Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
AD  - Dutch Childhood Oncology Group, The Hague, The Netherlands.
AD  - Erasmus University Medical Center, Rotterdam, The Netherlands.
FAU - Kaspers, Gertjan J L
AU  - Kaspers GJL
AD  - Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Pediatric 
      Oncology, Cancer Center Amsterdam, Amsterdam, The Netherlands.
AD  - Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
AD  - Dutch Childhood Oncology Group, The Hague, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20191223
PL  - United States
TA  - Pediatr Blood Cancer
JT  - Pediatric blood & cancer
JID - 101186624
SB  - IM
MH  - Adolescent
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Humans
MH  - Incidence
MH  - Infant
MH  - Infant, Newborn
MH  - Leukemia, Myeloid, Acute/*mortality/*therapy
MH  - Male
MH  - Retrospective Studies
MH  - Young Adult
OTO - NOTNLM
OT  - death in CR1
OT  - outcome
OT  - pediatric acute myeloid leukemia/pediatric AML
OT  - toxicity
OT  - treatment-related mortality
EDAT- 2019/12/25 06:00
MHDA- 2020/06/27 06:00
CRDT- 2019/12/25 06:00
PHST- 2019/10/06 00:00 [received]
PHST- 2019/11/02 00:00 [revised]
PHST- 2019/11/05 00:00 [accepted]
PHST- 2019/12/25 06:00 [pubmed]
PHST- 2020/06/27 06:00 [medline]
PHST- 2019/12/25 06:00 [entrez]
AID - 10.1002/pbc.28099 [doi]
PST - ppublish
SO  - Pediatr Blood Cancer. 2020 Apr;67(4):e28099. doi: 10.1002/pbc.28099. Epub 2019 
      Dec 23.